Corona Virus

House Dems raise issues with ‘atypical’ FDA review process for Alzheimer’s drug

The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it won the FDA’s backing despite questions about the drug’s clinical benefit to patients.Read More

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top